Bloomberg News

TiGenix Rheumatoid Arthritis Trial Moves to Randomized Stage

October 25, 2011

Oct. 25 (Bloomberg) -- TiGenix NV got approval from the independent Safety Monitoring Board to move its Phase IIa clinical trial in rheumatoid arthritis into randomized recruitment.

“This decision is based on the analysis of the safety data from patients treated in the study’s first cohort,” TiGenix said today in an e-mailed statement.

To contact the editor responsible for this story: Andrew Clapham at aclapham@bloomberg.net


Race, Class, and the Future of Ferguson
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus